Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B lands $135mm for Beam Therapeutics

Executive Summary

Beam Therapeutics Inc. (developing genetic medicines through base editing) raised $135mm in its Series B financing to first-time backers Redmile Group, Cormorant Asset Management, GV, and Altitude Life Science Ventures, and returning shareholders F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, and Omega Funds, as well as undisclosed investors. The company will use the funds to advance next-generation CRISPR technologies, expand its pipeline, and expand its scientific and technical leadership.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies